All News

Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.

Johnson & Johnson and its Janssen Pharmaceutical Cos unit have agreed to a more than $10 million settlement, rather than allowing the matter go to federal trial.

The FDA’s accelerated approval program has been criticized recently for pushing drugs into the market before they undergo randomized phase 3 clinical trials.

Many critics have accused Oliver of oversimplifying a complex issue.

Rite Aid has officially launched the annual Pharmacy Champions program, which is held every October during American Pharmacists Month.

Study shows the importance of a cancer-causing oncogene, known as SET/TAF1, in triggering cancer cell proliferation.

The National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institute of Health, has developed the Collaborative Influenza Vaccine Innovation Centers (CIVICs) program.

Officials from the FDA have granted Geron Corporation’s imetelstat fast track designation for adult patients with intermediate-2 or high-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment.

Researchers from John Hopkins Medicine have successfully used microscopic man-made particles to help predict early signs of severe chronic obstructive pulmonary disease (COPD) in patients.

Seventeen million children and adults in the United States are currently living with ADHD. Each October, ADHD Awareness Month is celebrated with different events, activities, and resources to continue shining the light on the disorder.

Top news of the day from across the health care landscape.

Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.

Why is a young patient using a topical steroid for vitiligo?

Top news of the day from across the health care landscape.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

The report highlighted the reasoning for the drug shortage as well as specific applicants and manufacturers that the agency will be working with to mitigate the supply of Ig products.

Along with her B.S. in pharmacy from UNC-Chapel Hill, author Amy Greeson’s education has included some much more unique experiences. She’s been to Belize to study native therapies, studied in the Amazon with a local medicine man and woman, and learned from traditional healers in Mexico.

The FDA has given the green light to rituximab (Rituxan) injection for the treatment of granulomatosis with polyangiitus (GPA) and microscopic polyangiitis (MPA) in children age 2 and older in combination with glucocorticoids. The application was approved under priority review and with orphan designation.

Research discusses specific mindsets that could affect the health of patients with cancer: regarding the disease as either a catastrophe or an opportunity and seeing the body as either a friend or foe.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Wednesday was World Pharmacist Day, and pharmacists all around the world celebrated their profession. We asked why you were thankful to be a pharmacist and how you were celebrating, and you responded!

The NFID released data that revealed only 52% of adults in the country plan to get vaccinated against the flu this season.

Ahead of World Heart Day, Amgen has released a study demonstrating that patient education is still necessary to combat cardiovascular disease.

Daratumumab was approved based on results from part one of the Phase III CASSIOPEIA study.

Patients with metastatic colorectal cancer harboring certain non-V600 BRAF mutations may benefit from anti-EGFR treatment.

Value assessment frameworks are expected to play a more pivotal role in decisions that affect future patient choice and access.

The vitamin D and omega-3 clinical trial (VITAL) is the largest, most recent study to test this subject matter, with nearly 26,000 United States men and women participating in the trial.